Unlocking the Potential of Immuno-Oncology Using Masked Bi- & Multispecifics
- Xilio is deploying its clinically validated masking technology to advance several highly differentiated bi- and multispecific molecules towards clinical development
- XTX501, Xilio’s PD1/masked IL-2 bispecific has the potential to be a foundational backbone therapy for combination regimens across a broad range of solid tumors, and the program is on track to advance into the clinic this year
- XTX601, Xilio’s masked CLDN18.2 T-cell engager and Xilio’s masked PSMA+STEAP1 dual-TAA targeted T-cell engager with co-stimulation both have firstin- class potential and further demonstrate the power of our masking technology to unlock the potential of T-cell engagers